Intec Pharma Ltd. (TASE: INTP) has reported successful final results of its Phase II clinical trial for the Zaleplon accordion pill, for the treatment of chronic insomnia. Intec Pharma develops improved versions of current drugs, and currently has hundreds of millions of dollars a year in sales.
83 patients suffering from chronic Insomnia participated in the trial. The trial achieved its primary endpoints. The trial registered brain waves and eye movements, through which it was able to evaluate the time to sleep onset, sleep duration, and level of alertness the next morning (residual effects of the drug).
An analysis of the trial results indicated that there was a statistically significant decrease of the time to sleep onset (LPS- Latency to persistent sleep), a statistically significant increase of sleep duration (TST- Total sleep time), and no residual effects the next morning, following treatment with the Accordion Pill Zaleplon, compared with a placebo.
Intec Pharma's share price rose 9.4% by midday to NIS 1.02, giving a market cap of NIS 171 million.
Published by Globes [online], Israel business news - www.globes-online.com - on November 22, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011